Psoriatic arthritis surgery could involve removing damaged tissue or bone or replacing a joint with severe damage. Learn more ...

The global psoriatic arthritis (PsA) treatment market is poised for remarkable expansion, with an anticipated valuation of ...

Treatment of psoriatic arthritis has tended to follow evidence-based strategies for achieving remission or minimal disease activity in rheumatoid arthritis. However, distinct immunopathogenic ...

should be the target of all treatment strategies in psoriatic arthritis. All musculoskeletal and cutaneous manifestations of psoriatic disease need to be considered in treatment targets.

Plaque psoriasis (PsO) and psoriatic arthritis (PsA) are lifelong conditions that can have a significant impact on those ...

2–5 Both the European Alliance of Associations for Rheumatology (EULAR) recommendations and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis recommendations have put forward ...

When compared with other biologic therapies, patients with psoriasis receiving IL-23 inhibitors had a lower risk for inflammatory arthritis or psoriatic arthritis development.

UCB, a global biopharmaceutical company, today announced the start of BE BOLD, a head-to-head Phase 3b study, comparing BIMZELX® (bimekizumab-bkzx), an interleukin (IL)-17A and IL-17F inhibitor, with ...